Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Total Non-Current Liabilities (2019 - 2020)

Avidity Biosciences (RNA) has disclosed Total Non-Current Liabilities for 2 consecutive years, with $26.0 million as the latest value for Q3 2020.

  • For the quarter ending Q3 2020, Total Non-Current Liabilities changed N/A year-over-year to $26.0 million, compared with a TTM value of $26.0 million through Sep 2020, changed N/A, and an annual FY2019 reading of $27.5 million, changed N/A over the prior year.
  • Total Non-Current Liabilities was $26.0 million for Q3 2020 at Avidity Biosciences, up from $25.1 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $27.5 million in Q4 2019 and bottomed at $25.1 million in Q2 2020.